ACRSAclaris Therapeutics, Inc.

$435M

Q4 2024 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$9M-47.6% YoY

Gross Profit

-$90,000-1.0% margin

Operating Income

-$100M-1082.1% margin

Net Income

-$97M-1048.2% margin

EPS (Diluted)

$-1.01

QoQ Revenue Growth

+111.9%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$45M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$220M

Total Liabilities

$65M

Stockholders' Equity

$156M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$18M	-47.6%
Gross Profit	-$90,000	$11M	-100.8%
Operating Income	-$100M	-$4M	-2362.9%
Net Income	-$97M	-$1M	-6375.7%

Revenue Segments

License and Service

$11M90%

Contract research

$1M10%

ACRS Q4 2024 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena